Cellectar BioSciences reported a FY 2025 net loss of USD 21.8 million, or USD 8.35 per basic and diluted share. R&D expenses were USD 11.5 million and G&A expenses were USD 11.5 million for FY 2025, with total operating expenses of USD 23.0 million. Other income, net was USD 1.2 million, including a USD 0.8 million gain on valuation of warrants and USD 0.4 million interest income. Cash and cash equivalents were USD 13.2 million as of December 31, 2025, and the company said this is adequate to fund basic budgeted operations into Q3 2026. On the business side, Cellectar said it remains on track to submit a Conditional Marketing Authorization to the EMA in Q3 2026 for iopofosine I 131 in Waldenström Macroglobulinemia, supported by CLOVER WaM data including 12-month follow-up. The company also noted iopofosine I 131 has FDA Breakthrough Therapy Designation in relapsed/refractory Waldenström Macroglobulinemia and that the FDA recommended investigating the therapy in post-BTKi indications as early as second line. Cellectar also initiated a Phase 1b dose-finding study of CLR 125 in triple negative breast cancer, with early data expected by mid-year 2026, and highlighted a supply agreement with Ionetix for commercial-scale cGMP-grade Actinium-225 and Astatine-211 to support CLR 225 development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603040715PRIMZONEFULLFEED9665497) on March 04, 2026, and is solely responsible for the information contained therein.
Comments